Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seid Hamzic

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pharmacogenomics|May 23, 2018
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?Seid Hamzic, Ursula Amstutz, Carlo R Largiadèr
Swiss Medical Weekly|November 24, 2020
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised TherapySeid Hamzic, Stefan Aebi, Markus Joerger, et al.
Journal of Chemical Information and Modeling|June 23, 2022
Predicting In Vivo Compound Brain Penetration Using Multi-task Graph Neural NetworksSeid Hamzic, Richard Lewis, Sandrine Desrayaud, et al.
Journal of Personalized Medicine|October 22, 2020
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic StudiesDominic Schaerer, Tanja K Froehlich, Seid Hamzic, et al.
British Journal of Clinical Pharmacology|January 25, 2021
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicitySeid Hamzic, Dominic Schärer, Steven M Offer, et al.
Pharmacological Research|December 16, 2019
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysisSeid Hamzic, Dominic Kummer, Tanja K Froehlich, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pharmacogenomics|May 23, 2018
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?Seid Hamzic, Ursula Amstutz, Carlo R Largiadèr
Swiss Medical Weekly|November 24, 2020
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised TherapySeid Hamzic, Stefan Aebi, Markus Joerger, et al.
Journal of Chemical Information and Modeling|June 23, 2022
Predicting In Vivo Compound Brain Penetration Using Multi-task Graph Neural NetworksSeid Hamzic, Richard Lewis, Sandrine Desrayaud, et al.
Journal of Personalized Medicine|October 22, 2020
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic StudiesDominic Schaerer, Tanja K Froehlich, Seid Hamzic, et al.
British Journal of Clinical Pharmacology|January 25, 2021
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicitySeid Hamzic, Dominic Schärer, Steven M Offer, et al.
Pharmacological Research|December 16, 2019
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysisSeid Hamzic, Dominic Kummer, Tanja K Froehlich, et al.
Pageof 1